Materials and Methods
Reagents. The LTB 4 receptor antagonist CP-105,696 was synthesized as previously described (15) . RPMI medium supplemented with 10 mM Hepes buffer, 100 U/ml penicillin-streptomycin, 0.1 mM nonessential amino acids, 2 mM t-glutamine, 1 mM sodium pyruvate, and 0.05 mM 2-ME was used for culturing T cells. All components were obtained from BioWhittaker Inc. (Walkersville, MD).
Encephalogenic Protein. A previously described encephalogenic peptide (acetyI-FFKNIVTPI~TPPP-amide) (16) corresponding to regions 91-103 of guinea pig myelin basic protein was prepared by the Protein Chemistry Division at Pfizer, Inc. All reagents were characterized by electrospray mass spectra (Firmegan TSQ-700) and amino acid analysis (ABI 420A) and were found to have had a single peak by reverse-phase HPLC.
Animals. Female SJL mice were obtained from The Jackson Laboratory (Bar Harbor, ME) at 6--8 wk of age. Animals were acclimated in-house for a minimum of 2 wk before use and were allowed food and water ad lib. Animals were routinely checked for pathogens and were always kept in microisolator cages.
Passive Transfer Model of EAE. EKE was induced in animals using the passive transfer model as previously described (17) . Mice were immunized in three separate areas on the lower back once a week for 2 wk with an emulsion containing 30 Izg H37RA
Mycobacte~um tuberculosis (3114-33-8 ; Dffco Laboratories Inc., Detroit, MI), 75 I~I PBS, 75 I~I IFA (0639-60-6; Difco Laboratories Inc., Detroit, MI) and 75 l~g of the encephalogenic peptide. Spleens or lymph nodes (inguinal, brachial, and axilhry) were collected 7 d after the last immunization. A single-cell suspemion was made, and cells were placed into culture using T-225 flasks (Costar Corp., Cambridge, MA) for 4 d at a density of 3 X 106 cells/ml in RPMI medium containing 10% FCS and 5 ~g/m.1 of the encephalogenic peptide. Cells were also plated into 96-well plates to determine proliferative responses to the antigen over the 4-d period using [3H]thymidine incorporation as a guide. After the culture period, the cells were collected, layered over Histopaque (1077-I; Sigma Chemical Co., St. Louis, MO), and centrifuged at 800 g for 15 rain. Lymphocytes were then collected, washed, adjusted to 2.5 X 108 lymphobhsts/ml in PBS (the lymphoblasts were confirmed by FACS | analysis to be CD4 + IL-2R + cells). 200 I~I of the cell suspemion was then injected intraperitonealIy into naive mice. Unless otherwise indicated, CP-105,696 was orally administered on a daily basis beginning at the time of T cell injection.
Paralysis was monitored on a daffy basis according to the following criteria: (a), limp tail; (b), hind limb weakness; (c), one hind limb paralyzed; (d), both hind limbs paralyzed; (e), moribund; (f), death. Each group contained a minimum of five animals and were allowed access to food and water at the cage base. Moribund animals were killed. The mean disease severity for each group was plotted over the study period, and the area under the curve was calculated. The percent inhibition of disease severity was then calculated compared with the placebo-treated controis. The animal weight was also determined at various time points during the course of disease.
Biochemical Measurements. The selective eosinophil enzyme, eosinophil peroxidase (EPO), was measured as previously described (18) . Spinal cords were homogenized, subjected to two freezethaw cycles, and centrifuged at 1,000 g for 30 min. As a standard, serial dilutions of a lysed suspension of 2.5 X 104 eosinophils/ml were used.
Microscopic Studies. Samples for light microscopy were prepared by removing brain and selected portions of the spinal cord and fixing by immersion in 10% neutral-buffered formalin for 12-18 h. The fixed specimem were trimmed, processed, and embedded in paraflSn using standard techniques. 5-1~m thick sections were cut on a microtome (Autocut; R.eichert Jung, Vienna, Austria), stained with hematoxylin and eosin, and viewed with a microscope (FXA; Nikon Inc., Melville, NY).
Samples for dectron microscopic examination were prepared by removing small portions of the formalin-fixed spinal cord and fixing for 1 h by immersion in 3% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2, 4~
The tissue was then processed and embedded in epoxy resin. Thin sections were cut on a ultramicrotome (model FC-4, 1Leichert Jung), stained with uranyl acetate, and viewed on an electron microscope (model 1200; JEOL USA, Peabody, MA).
Statistics. The results are expressed as the mean -+ 1 SD. Statistical analysis was done using the Student's t test and the MannWhimey U test. A P value of <0.05 was considered significant. The area under the curve was calculated using the trapezoidal rule.
Results
The paralysis induced in mice after the administration of encephalogenic T cells could be completely prevented by the administration of a 20-mg/kg dose of the LTB4 receptor antagonist CP-105,696 ( Fig. 1) . At a lower dose of 10 mg/kg, disease severity was reduced by up to three disease scores or 65% at day 38. The serum level of CP-105,696 18 h after the seventh daily oral treatment with 10 mg/kg was The data represent a total of three studies using a minimum office animah per group. Treatments were administered per os daily for 15 d beginning at the time of passive transfer. *P <0.05.
90-100 I~g/ml. This level of drug blocks LTB4 (100 nM)-mediated upregulation of the complement receptor ( C D l l b / C D 1 8 ) on neutrophils in mouse whole blood by >95%. I n addition, although rare, in cases where some death was observed in the control groul~, CP-105,696 was also able to prevent mortality (data not shown).
As shown in Table 1 , the etticacious effects o f C P -105,696 could be observed using three different parameters o f disease scoring: a decrease in total disease over the 40-d period (area under the curve), a decrease in maximum disease severity, and a prolongation of the day o f disease onset.
However, when treatment was initiated after the onset of symptoms, when high numbers o f eosinophils are already present, no protective effects were observed (data not shown).
Histological examination of the brain and upper segment of the spinal cord of EAE animals revealed cellular infiltrates consisting primarily of lymphocytes at the light microscopic level. In contrast, the composition o f the cellular infiltrate was different in the lower spinal cord near the cauda equina, where a large number o f eosinophils in addition to lymphocytes were observed (Fig. 2 13) . In this area of the spinal cord, the leukocytes appeared to penetrate the neural tissue along the course of the supplying vessels. In addition, large numbers ofleukocytes and degenerating axons were observed in the surrounding nerve roots. Fig. 3 illustrates a section o f the lower area of the spinal cord examined at the electron microscopic level. The characteristic eosinophil granules can be observed, which in many instances had been released within the extracellular matrix. In C) and electron (data not shown) microscopic level. In contrast, the effects of CP-105,696 on lymphocyte infiltration were minimal and did not reflect the protective effects observed with this agent on paralysis.
To better quantify the reduction in eosinophil infiltration, the amount of EPO was measured. EPO levels are detectable at times coincident with the appearance of paralysis in animals. When animals were treated with CP-105,696, up to a two-log reduction in the level of EPO in the spinal cord was observed compared with vehicletreated animals (Fig. 4) . Animals that did not receive encephalogenic cells had no detectable cellular infiltration into the spinal cords and no detectable EPO levels. • addition, we also observed eosinophils within apparently intact myelinated sheaths replacing the axon (Fig. 3 B) in the nerve rootlets surrounding the lower spinal cord, suggesting a compromise in integrity upstream from the section. In animals treated with CP-105,696, a decrease in eosinophil infiltration was observed at both the light (Fig. 2 
Discussion
Previous studies have indicated the important role for CD4 + T cells in the pathogenesis of EAE (4). Although lymphocytes may be responsible for initiating the disease, the actual disease pathology may be mediated by various inflammatory cells. We demonstrated that by blocking the LTB 4 receptor, the development of paralysis and the recruitment of eosinophils into the spinal cord was prevented. These studies indicate that eosinophil infiltration was dependent on LTB4 receptor ligation and reveal an important role for eosinophils in this disease as illustrated by the ability of CP-105,696 to inhibit disease coincident with a decrease in eosinophil, but not lymphocyte, numbers in the spinal cord. Although it could be argued that CP-105,696 is inhibiting additional factors necessary for eosinophil infiltration, previous studies have indicated the selectivity for this agent for the LTB 4 receptor, as indicated by its inability to inhibit the activity of other G protein-receptor agonists, including IL-8, C5a, and PAF (13) . It also has no effect on leukotriene or prostaglandin biosynthesis nor on IL-l-induced neutrophil accumulation in vivo (14) .
There are two possible ways that LTB 4 might stimulate eosinophil infiltration. The first is by direct chemotactic effects on the eosinophil LTB 4 receptor. LTB4 has been shown to induce eosinophil chemotaxis (11) , and CP-105,696 has been demonstrated to block this effect (13) . However since LTB 4 is also chemotactic for neutrophils, which were not observed in tissue, a direct cell-recruiting effect is unlikely. The second, perhaps more likely, mechanism is by stimulating encephalogenic T cells (7) to release eosinophil-chemotactic agents. Kecently, encephalogenic T cells have been shown to express message levels for several chemokines (6) , including the eosinophil chemoattractants macrophage inflammatory protein (MIP) la and KANTES (19, 20) . Although this mechanism cannot be tested at this time since neutralizing antibodies and specific ELISAs to these chemokines are not commercially available, a report has indicated that neutralizing antibodies to MIP-I(x will prevent paralysis in EAE (21) .
Although they have been observed in the spinal fluid of MS patients (22, 23) , eosinophils have not been previously implicated in promoting the disease pathology associated with EAE. Whereas lymphocytes clearly are present in the CNS, our studies indicate that decreasing eosinophil but not lymphocyte infiltration was associated with inhibition of paralysis. EAE is an ascending disease of the CNS such that damage occurs first to the lower area, where the myelinated axons supplying the tail and hind limbs originate. As such, damage to this area would more closely correlate with hind-limb paralysis. Therefore the role of eosinophils in EAE may have been underestimated in previous studies, which have usually concentrated on the upper areas of the spinal cord and brain (24) . In addition, studies illustrating selective inhibition of eosinophil rather than lymphocyte recruitment have not been done. A decrease in the number of eosinophils shown histologically and enzymatically correlated with a favorable outcome in animals treated with CP-105,696. Our electron microscopic observations demonstrating eosinophils within the myelin sheath further support the hypothesis that these cells may be involved in axonal atrophy and paralysis. In addition, as a proof of concept, an eosinophil-derived neurotoxin has been reported to induce EAE-like paralysis when injected into naive animals (25) .
In summary, LTB4 receptor ligation was responsible for mediating eosinophil influx into the lower spinal cord of animals during EAE. These eosinophils are important mediators of paralysis, since treatment with the specific LTB 4 receptor antagonist CP-105,696 selectively decreased eosinophil infiltration into the CNS and concomitantly prevented disease symptoms. The lack of effects of CP-105,696 when treatment was initiated after the onset of symptoms and when large numbers of eosinophils are already present suggests that continued eosinophil infiltration is not important for the progression of disease. Studies are in progress to assess the pathological role of eosinophils on secondary relapses.
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